Alexander Sedkov

Aromatic L‐Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease

J. Nutt, C. Christine, P. Larson, 2020, Movement disorders : official journal of the Movement Disorder Society.

Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease

R. Pahwa, H. Murck, R. Batycky, 2017, Journal of aerosol medicine and pulmonary drug delivery.

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

H. Colman, B. V. Van Tine, S. Guichard, 2022, Neuro-oncology.

Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study.

W. Poewe, O. Rascol, J. Kassubek, 2019, Parkinsonism & related disorders.

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial

R. Pahwa, R. Hauser, H. Fernandez, 2019, The Lancet Neurology.

The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer.

M. Reimers, N. Shore, M. Gordon, 2021 .

Abstract P202: Initial findings from an ongoing first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer

E. Lam, A. Armstrong, A. Hussain, 2021, Poster Presentations - Proffered Abstracts.

A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine.

H. Colman, M. Milhem, M. Rosenthal, 2020 .